As of November 30, 2024, Fosun Pharma conducted multiple repurchases of its ordinary shares listed in Hong Kong on the Hong Kong Stock Exchange (H股), totaling 862,500 shares, which are held as treasury stock. The repurchase activities took place on November 1, 25, 26, and 27, at repurchase prices ranging from HK$14.03 to HK$14.92 per share. Due to these repurchases, the number of issued shares decreased to 545,606,500 shares, while the treasury shares increased to 6,334,000 shares. In terms of statutory/registered capital, the statutory capital of Fosun Pharma's H shares and A shares remains unchanged at RMB 551,940,500 and RMB 2,119,385,965 respectively, totaling RMB 2,671,326,465. The company confirms that all repurchase activities have been authorized by the board of directors and conducted in accordance with relevant laws and regulatory requirements. In the future, the company will continue to monitor market dynamics and adjust the share structure in a timely manner to optimize capital allocation.

As of November 30, 2024, Fosun Pharma conducted multiple repurchases of its ordinary shares listed in Hong Kong on the Hong Kong Stock Exchange (H股), totaling 862,500 shares, which are held as treasury stock. The repurchase activities took place on November 1, 25, 26, and 27, at repurchase prices ranging from HK$14.03 to HK$14.92 per share. Due to these repurchases, the number of issued shares decreased to 545,606,500 shares, while the treasury shares increased to 6,334,000 shares. In terms of statutory/registered capital, the statutory capital of Fosun Pharma's H shares and A shares remains unchanged at RMB 551,940,500 and RMB 2,119,385,965 respectively, totaling RMB 2,671,326,465. The company confirms that all repurchase activities have been authorized by the board of directors and conducted in accordance with relevant laws and regulatory requirements. In the future, the company will continue to monitor market dynamics and adjust the share structure in a timely manner to optimize capital allocation.